News
-
Specialty pharmaceutical research company’s new retinal vascular dysfunction model can have a major impact on research and development of new drugs for retinal vascular diseases.
ALBANY, N.Y., September 26, 2023 (Newswire.com) - Humonix Biosciences, Inc., has developed a new 3D human tissue model, called the retinal vascular dysfunction model.
Humonix’s new model is a physiologically relevant 3D model of the blood-retinal barrier. This model expresses key physiological and biological characteristics, providing a platform for testing therapies related to retinal vascular dysfunction.
Humonix’s new model incorporates two cell types, whereas most current in vitro models utilize a single cell type, thereby missing important determinants of barrier function. Humonix’s retinal vascular dysfunction model can recapitulate organ-specific vascular dysfunction, and therefore be applied to diseases such as macular edema and diabetic retinopathy.
This novel model can aid in the drug development process and expedite progress of life-changing therapies for patients living with retinal vascular diseases.
"During discussions with key opinion leaders and drug developers, we saw a trend that in vitro models and, to a certain extent, animal models are not good at narrowing down the best clinical candidates. The significant lack of models of the blood-retinal barrier that incorporate human retinal cells and mimic the pathophysiology of diabetic retinopathy and diabetic macular edema hampers the chances of identifying high-potential candidates to move forward in the drug development pipeline. We at Humonix are proud to have engineered a 3D human tissue model of the blood-retinal barrier that can accelerate the development of new and improved therapies."
- Karen Torrejon, PhD, Chief Scientific Officer, Humonix
"A reproducible and approachable model of the blood-retinal barrier needs to be more complex than a monolayer of cells; interactions between endothelial cells and pericytes are central to the development and maintenance of barrier function, a fact well recapitulated in the Humonix model."
- Patricia A. D’Amore, PhD, MBA, Associate Chief for Basic and Translational Research, Mass Eye and Ear and Humonix Scientific Advisor
-
Specialty pharmaceutical research company celebrates the launch of a new service offering and with it, a brand refresh.
ALBANY, N.Y., July 11, 2023 (Newswire.com) - Glauconix Biosciences, Inc. is now Humonix Biosciences, Inc.
What began as a specialization in glaucoma therapeutics has become a launchpad for developing new fibrotic and vascular 3D human tissue models. The company is proud to announce a new retinal vascular dysfunction 3D model proven to express key physiological and biological characteristics. The new model can help along all aspects of the drug development process and expedite drug development by utilizing 3D human tissue, which has greater translatability and quicker turnaround times than other more traditional pre-clinical testing methods.
Now that the company has expanded beyond glaucoma and successfully proven that the platform technology can support various cell types, the company has changed its name to Humonix Biosciences. This move is reflective of a larger breadth of service offerings and a vision to expand the 3D human tissue systems to address other diseases in the body.
"This is a very exciting time for us as we move closer to our vision to make all fibrotic and vascular diseases treatable. We are making good on our commitment to our customers to relentlessly innovate and create new opportunities for breakthrough therapies to succeed." - Kimberly Southern, Chief Executive Officer, Humonix
"It's a transformational time for Humonix as they expand their industry-leading platform technology to address the significant unmet need in the marketplace for validated fibrotic and vascular 3D tissue models. I'm excited to continue supporting the company and looking forward to seeing what comes next!" - Robert Dempsey, Chief Executive Officer, President, AsclepiX Therapeutics, Inc and Humonix Board Member